Advertisement

Topics

New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug

12:51 EDT 19 Jun 2017 | Xconomy

Clovis Oncology received a short-cut approval from the FDA last year for its ovarian cancer drug that treats women with the common BRCA genetic mutation. Clovis (NASDAQ: CLVS) said Monday it now has evidence that the drug, rucaparib (Rubaca), can treat a wider swath of patients, and it will ask the FDA for approval this […]

Original Article: New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug

NEXT ARTICLE

More From BioPortfolio on "New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...